STAT July 5, 2024
Rohan Rajeev

New research finds that the GLP-1 class of drugs — glucagon-like peptide receptor agonists — is more effective in mitigating the risk of 10 obesity-associated cancers than its type 2 diabetes drug alternatives.

The retrospective study, published Friday in JAMA Network Open, measured results for a cohort of more than 1.6 million patients with type 2 diabetes from 2005 to 2018 who were prescribed...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Pharma / Biotech, Survey / Study, Trends
In sustained rare disease push, Recordati lays out $825M upfront to acquire Sanofi's CAD drug Enjaymo
Pharma Pulse 10/3/24: Data Collection Complexities, 8 Things You May Not Know About Breast Cancer & more
New Techniques Make RNA Accessible to Study Variants of Uncertain Significance
Comprehensive strategies for prescription drug cost management
Gilead strikes deal to expand HIV drug access in 120 countries

Share This Article